KalVista Pharmaceuticals Inc’s recently made public that its CHIEF DEVELOPMENT OFFICER Yea Christopher unloaded Company’s shares for reported $25553.0 on Feb 18 ’25. In the deal valued at $9.82 per share,2,601 shares were sold. As a result of this transaction, Yea Christopher now holds 92,745 shares worth roughly $0.96 million.
Then, Audhya Paul K. sold 3,125 shares, generating $30,701 in total proceeds. Upon selling the shares at $9.82, the CHIEF MEDICAL OFFICER now owns 100,334 shares.
Before that, Palleiko Benjamin L sold 5,104 shares. KalVista Pharmaceuticals Inc shares valued at $50,143 were divested by the CHIEF EXECUTIVE OFFICER at a price of $9.82 per share. As a result of the transaction, Palleiko Benjamin L now holds 278,855 shares, worth roughly $2.89 million.
JMP Securities initiated its KalVista Pharmaceuticals Inc [KALV] rating to a Mkt outperform in a research note published on January 31, 2025; the price target was $19. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. BofA Securities began covering KALV with “Buy” recommendation on December 18, 2024. H.C. Wainwright started covering the stock on June 15, 2020. It rated KALV as “a Buy”.
Price Performance Review of KALV
On Friday, KalVista Pharmaceuticals Inc [NASDAQ:KALV] saw its stock jump 3.19% to $10.35. Over the last five days, the stock has gained 6.05%. KalVista Pharmaceuticals Inc shares have risen nearly 22.20% since the year began. Nevertheless, the stocks have fallen -20.63% over the past one year. While a 52-week high of $15.50 was reached on 02/19/25, a 52-week low of $7.30 was recorded on 01/13/25. SMA at 50 days reached $8.92, while 200 days put it at $11.10.
Levels Of Support And Resistance For KALV Stock
The 24-hour chart illustrates a support level at 10.02, which if violated will result in even more drops to 9.68. On the upside, there is a resistance level at 10.61. A further resistance level may holdings at 10.87. The Relative Strength Index (RSI) on the 14-day chart is 62.57, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.55, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 30.09%. Stochastics %K at 70.51% indicates the stock is a holding.
The most recent change occurred on July 29, 2019 when SVB Leerink began covering the stock and recommended ‘”an Outperform”‘ rating along with a $31 price target.
